Drometrizole trisiloxane API Manufacturers

General Description:

Drometrizole trisiloxane, identified by CAS number 155633-54-8, is a notable compound with significant therapeutic applications. Drometrizole trisiloxane is a photostable UVA and UVB light filter . The compound is a lipophilic benzotriazole derivative marketed as Meroxyl XL by L'Oreal, although sunscreens with drometrizole trisiloxane are currently only approved for use in the EU, Canada, Australia, and Japan, among other countries. Despite being used elsewhere in the world with relatively few reports of adverse reactions, the FDA continues to cite that the existing scientific record is not sufficient to establish the compound as being generally recognized as safe and effective for over-the-counter sunscreen use .

Indications:

This drug is primarily indicated for: Drometrizole trisiloxane is used as an active ingredient in various sunscreens for the indication of protecting the skin by absorbing the damaging UV radiation of sunlight . Its use in specific medical scenarios underscores its importance in the therapeutic landscape.

Metabolism:

Drometrizole trisiloxane undergoes metabolic processing primarily in: Drometrizole trisiloxane is reported as having little to no absorption through the skin . The systemic presence of the compound is consequently expected to be minimal. This metabolic pathway ensures efficient processing of the drug, helping to minimize potential toxicity and side effects.

Absorption:

The absorption characteristics of Drometrizole trisiloxane are crucial for its therapeutic efficacy: Drometrizole trisiloxane is reported as having little to no absorption through the skin . At this time, however, studies demonstrate that the components of most commonly used sunscreens are likely absorbed into the skin at least to some extent - although penetration to deeper tissues and the cutaneous circulation remains limited . Despite the extensive use of sunscreen products around the world, there have been few reports of adverse effects related to their use . The drug's ability to rapidly penetrate into cells ensures quick onset of action.

Half-life:

The half-life of Drometrizole trisiloxane is an important consideration for its dosing schedule: Drometrizole trisiloxane is reported as having little to no absorption through the skin . The systemic presence of the compound is consequently expected to be minimal. This determines the duration of action and helps in formulating effective dosing regimens.

Protein Binding:

Drometrizole trisiloxane exhibits a strong affinity for binding with plasma proteins: Drometrizole trisiloxane is reported as having little to no absorption through the skin . The systemic presence of the compound is consequently expected to be minimal. This property plays a key role in the drug's pharmacokinetics and distribution within the body.

Route of Elimination:

The elimination of Drometrizole trisiloxane from the body primarily occurs through: Drometrizole trisiloxane is reported as having little to no absorption through the skin . The systemic presence of the compound is consequently expected to be minimal. Understanding this pathway is essential for assessing potential drug accumulation and toxicity risks.

Volume of Distribution:

Drometrizole trisiloxane is distributed throughout the body with a volume of distribution of: Drometrizole trisiloxane is reported as having little to no absorption through the skin . The systemic presence of the compound is consequently expected to be minimal. This metric indicates how extensively the drug permeates into body tissues.

Clearance:

The clearance rate of Drometrizole trisiloxane is a critical factor in determining its safe and effective dosage: Drometrizole trisiloxane is reported as having little to no absorption through the skin . The systemic presence of the compound is consequently expected to be minimal. It reflects the efficiency with which the drug is removed from the systemic circulation.

Pharmacodynamics:

Drometrizole trisiloxane exerts its therapeutic effects through: As an active ingredient in sunscreen products, drometrizole trisiloxane is applied directly onto human skin where it acts as a chemical sunscreen layer between skin and sunlight that also directly absorbs the UV sunlight radiation . Since drometrizole trisiloxane is also considered to have little to no absorption through the skin , little systemic exposure and pharmacokinetics are expected and users can freely wash off and re-apply the compound as necessary. The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.

Mechanism of Action:

Drometrizole trisiloxane functions by: Ultraviolet radiation is the invisible energy component to sunlight and consists of three wavelength ranges: (a) UVA is long-range UV radiation between 320-400nm . Although not as energetic as UVB, UVA can penetrate deep into the dermis . UVA can cause immediate tanning, premature skin aging, and can also play a role in the formation of some skin cancers . Approximately 95% of UVA from the sun passes through Earth's ozone layer . (b) UVB is short-wavelength UV radiation between 280-320nm . It is capable of penetrating the outer protective layer of the skin and is responsible for delayed tanning, sunburns, and most skin cancers . A large amount of UVB is absorbed by the ozone layer, however, as only 5% reaches the Earth's surface . (c) UVC is comprised of wavelengths between 100-280nm and is very energetic . It is very dangerous to all forms of life, even when the exposure is short . However, UVC radiation is generally filtered out by the ozone layer and never reaches the Earth . Ultimately, the shorter the wavelength, the more harmful the UV radiation - although shorter wavelength UV radiation is less able to penetrate the skin . Subsequently, drometrizole trisiloxane is a broad spectrum lipophilic benzotriazole derivative chemical sunscreen that is capable of absorbing UVA and UVB radiation . It is also photostable, meaning that it will not degrade in the presence of sunlight, unlike other UV filters like the widely used UVA absorber avobenzone . When combined with the UV blocker ecamsule, it has been shown that the two UV blockers elicit a synergistic effect involving an enhanced protective action for the skin against UVA and UVB radiation . Additionally, drometrizole trisiloxane is usually combined with other active sunscreen agents like titanium dioxide, avobenzone, and others to ensure the combined product covers or protects against as broad a spectrum of UV radiation as possible, considering drometrizole trisiloxane does not absorb against the entire range of UV radiation . And finally, at the molecular level, it is believed that the general structure of various UV blockers like drometrizole trisiloxane as aromatic molecules conjugated with carbonyl groups is capable of absorbing high energy ultraviolet rays and then consequently releasing that energy as less harmful, lower energy rays. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.

Toxicity:

Classification:

Drometrizole trisiloxane belongs to the class of organic compounds known as phenyl-1,2,3-triazoles. These are organic compounds containing a 1,2,3-triazole substituted by a phenyl group, classified under the direct parent group Phenyl-1,2,3-triazoles. This compound is a part of the Organic compounds, falling under the Organoheterocyclic compounds superclass, and categorized within the Azoles class, specifically within the Triazoles subclass.

Categories:

Drometrizole trisiloxane is categorized under the following therapeutic classes: Compounds used in a research, industrial, or household setting, Macromolecular Substances, Organosilicon Compounds, Polymers, Silicon Compounds. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.